There are 2789 resources available
1294P - 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1295P - Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
Presenter: Mathilde Bureau
Session: ePoster Display
1296P - Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Presenter: Alberto Bongiovanni
Session: ePoster Display
1298P - PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Presenter: Sally Lau
Session: ePoster Display
1299P - Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Presenter: Konstantinos Rounis
Session: ePoster Display
1300P - A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Presenter: lin wu
Session: ePoster Display
1301P - Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
Presenter: Ari VanderWalde
Session: ePoster Display
1302P - Immune signatures of second-line PD-1 immune checkpoint blockade
Presenter: Kenneth O'Byrne
Session: ePoster Display